Supercharging A New FDA: Marty Makary on Science, Power & Patients

All-In Podcast
01:29:43 Report Issue
Loading transcript... Click for full transcript

Chapters & Sections (126)

0:00 FDA Commissioner's Role and Background chapter 3
0:00 FDA Commissioner's Role and Background
0:52 Root Causes of Healthcare System Problems
2:07 Critique of Medical Dogma and Pandemic Response
3:04 Rebuilding Public Trust in Health Institutions chapter 2
3:04 Rebuilding Public Trust in Health Institutions
3:53 Challenging the FDA's Status Quo and Reform
5:10 FDA Accountability and Transparency Measures chapter 2
5:10 FDA Accountability and Reform Efforts
6:43 FDA Culture and Priorities Under New Leadership
7:17 US Biotech Competitiveness and Chinese Innovation chapter 3
7:17 US FDA's Workforce and Capacity Building
8:08 US Biotech Innovation vs. Chinese Competition
8:47 US Biotech Industry Competitiveness Challenges
9:43 Streamlining Clinical Trial Approval Processes chapter 2
9:43 Streamlining Clinical Trial Approval Processes
10:49 Streamlining FDA Regulatory Processes and Efficiency
12:09 FDA Reform and User Fee Reduction chapter 2
12:09 FDA Reform and User Fee Reduction
13:09 FDA Regulatory Burden on Drug Approvals
14:27 Reducing Animal Testing in Pharmaceutical Development chapter 3
14:27 Reducing Animal Testing in Pharmaceutical Development
15:40 Modernizing FDA Approval Process with Technology
16:30 Streamlining FDA Approval Process for New Drugs
17:35 Prioritizing New FDA Drug Approvals chapter 2
17:35 Prioritizing New FDA Drug Approvals Criteria
19:26 Accelerating Clinical Trial Approval Process
20:07 Accelerating Clinical Trials with Continuous Evaluation chapter 2
20:07 Accelerating Clinical Trials with Continuous Evaluation
21:25 Streamlining FDA Approval Process for Modern World
22:24 Real-Time Postmarket Surveillance for Drug Safety chapter 2
22:24 Improving Postmarket Surveillance with Big Data
23:32 Balancing Safety and Speed in Medical Innovation
24:33 Risks of Delaying FDA Approval Process chapter 2
24:33 Risks of Delaying FDA Approval Process
26:05 Regulatory Flexibility in Medical Research Funding
27:14 Streamlining Gene Therapy Manufacturing Regulations chapter 3
27:14 Regulatory Framework for Gene Therapies
28:01 Streamlining FDA Manufacturing Requirements
28:54 Gene Editing Therapies and Novel Regulatory Pathways
29:37 CARTT Therapy Advancements and Market Challenges chapter 3
29:37 CARTT Therapy Advancements and Market Challenges
30:41 FDA Inefficiencies and Digitization Challenges
31:22 Restructuring the FDA for Efficiency and Transparency
32:50 Critique of Food Pyramid and Nutrition Science chapter 2
32:50 Critique of Food Pyramid and Nutrition Science
34:14 Rise of Childhood Diabetes and Refined Carbohydrates
34:58 Importance of Protein in Modern Nutrition chapter 2
34:58 Importance of Protein in Modern Nutrition
36:19 The Corruption of Nutrition Science and Group Think
37:14 Challenging Dogma in Medical Science chapter 2
37:14 Challenging Medical Dogma and Misguided Recommendations
38:26 Industry Influence on Food Pyramid Guidelines
39:43 Impact of Insulin Resistance on Chronic Diseases chapter 3
39:43 Impact of Insulin Resistance on Chronic Diseases
40:45 Importance of Clean and Sustainable Food Sources
41:30 Obesity Epidemic and GLP1 Drug Benefits
42:12 Failure of Modern Food System and Health Consequences chapter 2
42:12 Failure of Modern Food System and Public Health
43:07 Benefits of Positive Thinking and Hormonal Supplementation
44:27 Government Funding for Scientific Research chapter 2
44:27 Government Funding for Scientific Research
45:49 Redirecting NIH Funding to Root Causes of Diseases
46:35 Limitations of Gene-Centric Approach to Health Research chapter 2
46:35 Limitations of Gene-Centric Approach to Health
47:28 NIH Funding Allocation and Research Priorities
48:46 Reforming the NIH and FDA Structure chapter 5
48:46 Addressing Health Disparities and Research Priorities
49:31 NIH Reforms and Vaccine Origins
50:18 Questioning Vaccine Recommendations and Schedule Changes
51:13 Parental Vaccine Choices and Social Consequences
51:47 Vaccine Schedule Criticism and Mislabeling
52:23 US Vaccine Schedule Compared to International Standards chapter 2
52:23 Comparing US Vaccine Schedule to International Standards
53:18 Vaccine Hesitancy and Medical Culture Disconnect
54:49 Decline in Childhood Vaccinations and Public Trust chapter 2
54:49 Decline in Childhood Vaccinations and Public Trust
56:25 Criticisms of Medical Experts with Impressive Credentials
57:01 Challenges in Vaccine Development and Safety chapter 3
57:01 Vaccine Safety and Effectiveness Concerns
58:01 Restoring Humility in American Medicine
58:47 Challenges in Medical Science and Healthcare Costs
59:41 Lowering Prescription Drug Prices in the US chapter 3
59:41 Lowering Prescription Drug Prices in the US
1:00:59 Lowering Drug Prices through FDA Reform
1:01:52 Streamlining Biosimilar Development Process
1:02:57 Why Prescription Drugs Should be Over-the-Counter chapter 3
1:02:57 Why Prescription Drugs Should Be Over-the-Counter
1:03:52 Price Transparency in Healthcare
1:04:27 Pharmaceutical Middlemen and Pricing Transparency
1:05:01 Simplifying Prescription Criteria for Over-the-Counter Medicines chapter 3
1:05:01 Streamlining Prescription Criteria for Over-the-Counter Drugs
1:05:46 Insurance Reimbursement for Over-the-Counter Medications
1:06:24 Modernizing Non-Prescription Drug Reimbursement Schemes
1:07:19 Opioid Overprescription and Antibiotic Misuse in Medicine chapter 3
1:07:19 Opioid Overprescription and Antibiotic Misuse in Medicine
1:08:02 Pharmaceutical Advertising Influence on Medical Professionals
1:09:14 Critique of Pharmaceutical Advertising Tactics
1:09:51 FDA Regulation of Pharmaceutical Advertising chapter 2
1:09:51 FDA Regulation of Pharmaceutical Advertising
1:11:17 Regulating AI in Healthcare and Medicine
1:12:32 Regulating AI-Powered Health Interventions and Wearables chapter 3
1:12:32 FDA Guidelines for AI-Powered Health Interventions
1:13:13 Regulation of Wearable Medical Devices
1:13:49 Regulation of Alternative Protein Production Methods
1:15:00 Alternative Protein Market and Food Dogma chapter 3
1:15:00 Alternative Protein Market and Food Dogma
1:16:12 Abuse of FDA's 'GRAS' Chemical Approval Process
1:16:57 Food Industry Chemical Safety Regulations Compared
1:17:40 Regulating Food Additives and Protein Content chapter 2
1:17:40 Regulating Food Industry and Protein Requirements
1:18:46 Causes and Rising Rates of Autism
1:19:40 Potential Causes of Pediatric Autoimmune Disorders chapter 2
1:19:40 Potential Causes of Pediatric Autoimmune Disorders
1:20:43 Impact of Modern Lifestyle on the Microbiome
1:21:58 Impact of Modern Diet on Children's Health chapter 2
1:21:58 Impact of Microbiome on Children's Health
1:23:35 Impact of Environmental Toxins on Human Health
1:24:13 Debunking Common Myths About Heart Disease chapter 3
1:24:13 Debunking Common Myths About Heart Disease
1:25:03 Reevaluating Dietary Fat and Heart Disease Research
1:25:46 Advancements in Cancer and Rare Disease Treatments
1:26:34 Addressing PTSD Treatment and Veterans' Mental Health chapter 3
1:26:34 Addressing PTSD in Veterans and Treatment Options
1:27:46 FDA Approval Process for Innovative Treatments
1:28:28 Streamlining the FDA Approval Process

Transcript

Loading transcript...